切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

RosetteSep™ HLA 淋系细胞富集试剂盒

免疫密度负选抗体混合物
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #15271HLA_C

免疫密度负选抗体混合物

产品优势

  • 操作简单、快速
  • 不需要特殊设备或培训
  • 分选得到的细胞不带标记

产品组分包括

  • RosetteSep™ HLA 淋系细胞富集试剂盒（产品号 #15271HLA）
    • RosetteSep™ HLA淋系细胞富集抗体混合物，5 x 2 mL
    • RosetteSep™ DM-L（产品号 #15705）x 2
main product photo
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. Lymphoprep™
    Lymphoprep™

    Density gradient medium for the isolation of mononuclear cells

  2. Dulbecco's Phosphate Buffered Saline with 2% Fetal Bovine Serum
    Dulbecco's Phosphate Buffered Saline with 2% ...

    Cell culture buffer

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

RosetteSep™ HLA淋系细胞富集抗体混合物为通过负选从全血中富集淋系（CD3+）细胞而设计，用于谱系特异性嵌合体分析。抗体四聚体复合物可识别CD16, CD19, CD20, CD36, CD56和红细胞（RBC）上的糖蛋白A，从而定向去除非目的细胞。使用密度梯度离心液如RosetteSep™ DM-L（产品号 #15705）离心时，非目的细胞会与红细胞一起沉淀。纯化的淋系细胞富集在血浆和密度梯度离心液的交界面处。获得的目的细胞可立即用于血清学、流式细胞术交叉配型检测或其他下游应用。请注意：鉴于欧洲议会和理事会关于体外诊断医疗器械的新欧盟法规2017/746 (IVDR)，已于 2022年生效，STEMCELL取消了这些产品的CE IVD注册并删除了相关声明，现在这些产品标注为 "仅供研究使用"。请注意，这些产品的外形、功能和质量保证没有任何变化。欲了解更多信息，请通过邮箱qaschangenote@stemcell.com 联系质量保证和法规部门。

亚型
细胞分选试剂盒
 
细胞类型
T 细胞
 
种属
人
 
样本来源
Buffy Coat，Whole Blood
 
筛选方法
Negative
 
应用
细胞分选，体外诊断
 
品牌
RosetteSep
 
研究领域
嵌合体，HLA，免疫
 

查看更多 显示更少

实验数据

FACS Histogram Results with RosetteSep™ HLA Lymphoid Cell Enrichment Kit

Figure 1. FACS Histogram Results with RosetteSep™ HLA Lymphoid Cell Enrichment Kit

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet 1
Product Name
RosetteSep™ HLA Lymphoid Cell Enrichment Kit
Catalog #
15271HLA
Lot #
Lots above 1000075249
Language
English
Document Type
Product Information Sheet 2
Product Name
RosetteSep™ HLA Lymphoid Cell Enrichment Kit
Catalog #
15271HLA
Lot #
Lots above 1000075249
Language
Multi
Document Type
Safety Data Sheet
Product Name
RosetteSep™ HLA Lymphoid Cell Enrichment Kit
Catalog #
15271HLA
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (4)

Cell Separation Products for HLA Analysis
Brochure
Cell Separation Products for HLA Analysis
Human Immune Cytokines
Wallchart
Human Immune Cytokines
Isolate Highly Purified Cells for HLA Analysis with RosetteSep™ Immunodensity Cell Isolation
1:21
Video
Isolate Highly Purified Cells for HLA Analysis with RosetteSep™ Immunodensity Cell Isolation
Isolate Cells from Whole Blood without Columns or Magnets: RosetteSep™ Immunodensity Cell Separation
2:19
Video
Isolate Cells from Whole Blood without Columns or Magnets: RosetteSep™ Immunodensity Cell Separati...

常见问题

What is RosetteSep™?

RosetteSep™ is a rapid cell separation procedure for the isolation of purified cells directly from whole blood, without columns or magnets.

How does RosetteSep™ work?

The antibody cocktail crosslinks unwanted cells to red blood cells (RBCs), forming rosettes. The unwanted cells then pellet with the free RBCs when centrifuged over a density centrifugation medium (e.g. Ficoll-Paque™ PLUS, Lymphoprep™).

What factors affect cell recovery?

The temperature of the reagents can affect cell recovery. All reagents should be at room temperature (sample, density centrifugation medium, PBS, centrifuge) before performing the isolations. Layering can also affect recovery so be sure to carefully layer the sample to avoid mixing with the density centrifugation medium as much as possible. Be sure to collect the entire enriched culture without disturbing the RBC pellet. A small amount of density centrifugation medium can be collected without worry.

Which cell samples can RosetteSep™ be used with?

RosetteSep™ can be used with leukapheresis samples, bone marrow or buffy coat, as long as: the concentration of cells does not exceed 5 x 107 per mL (can dilute if necessary); and there are at least 100 RBCs for every nucleated cell (RBCs can be added if necessary).

Can RosetteSep™ be used with previously frozen or cultured cells?

Yes. Cells should be re-suspended at 2 - 5 x 107 cells / mL in PBS + 2% FBS. Fresh whole blood should be added at 250 µL per mL of sample, as a source of red cells.

Can RosetteSep™ be used to enrich progenitors from cord blood?

Yes. Sometimes cord blood contains immature nucleated red cells that have a lower density than mature RBCs. These immature red cells do not pellet over Ficoll™, which can lead to a higher RBC contamination than peripheral blood separations.

Does RosetteSep™ work with mouse cells?

No, but we have developed EasySep™, a magnetic-based cell isolation system which works with mouse and other non-human species.

Which anticoagulant should be used with RosetteSep™?

Peripheral blood should be collected in heparinized Vacutainers. Cord blood should be collected in ACD.

Should the anticoagulant be washed off before using RosetteSep™?

No, the antibody cocktail can be added directly to the sample.

文献 (2)

Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. Vasir B et al. Journal of immunology (Baltimore, Md. : 1950) 2005 FEB

Abstract

The MUC1 transmembrane mucin is expressed on the surface of activated human T cells; however, the physiologic signals responsible for the regulation of MUC1 in T cells are not known. The present studies demonstrate that IL-7, but not IL-2 or IL-4, markedly induces MUC1 expression on CD3+ T cells. MUC1 was also up-regulated by IL-15, but to a lesser extent than that found with IL-7. The results show that IL-7 up-regulates MUC1 on CD4+, CD8+, CD25+, CD69+, naive CD45RA+, and memory CD45RO+ T cells. In concert with induction of MUC1 expression by IL-7, activated dendritic cells (DC) that produce IL-7 up-regulate MUC1 on allogeneic CD3+ T cells. DC also induce MUC1 expression on autologous CD3+ T cells in the presence of recall Ag. Moreover, DC-induced MUC1 expression on T cells is blocked by a neutralizing anti-IL-7 Ab. The results also demonstrate that DC induce polarization of MUC1 on T cells at sites opposing the DC-T cell synapse. These findings indicate that DC-mediated activation of Ag-specific T cells is associated with induction and polarization of MUC1 expression by an IL-7-dependent mechanism.
View publication
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Ueno NT et al. Blood 2003 NOV

Abstract

We evaluated the feasibility and efficacy of a reduced-intensity conditioning (RIC) regimen of fludarabine and melphalan to achieve rapid complete donor chimerism after allogeneic stem cell transplantation (SCT) in patients with metastatic solid tumors. Between January 1999 and January 2003, 8 patients with metastatic breast cancer (BC) and 15 with metastatic renal cell carcinoma (RCC) underwent allogeneic SCT after an RIC regimen of 5 days of fludarabine and 2 days of melphalan. Filgrastim-mobilized stem cells from HLA-identical related or unrelated donors were infused. Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus and methotrexate. All 22 evaluable patients had 100% donor chimerism at day 30 and at all measurement times thereafter. One patient died 19 days after SCT. Nine patients (39%) had grades II to IV acute GVHD and 10 patients (43%) had chronic GVHD. Five patients (22%) died of nonrelapse treatment-related complications. Treatment-related disease response was seen in 10 patients (45%), with 3 complete responses, 2 partial responses, and 5 minor responses. Fludarabine-melphalan is a feasible and effective RIC regimen for allogeneic SCT in metastatic BC and RCC. It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect.
View publication
View All Publications

更多信息

更多信息
种属 Human
样本来源 Buffy Coat, Whole Blood
Selection Method Negative
标记抗体
  1. 抗人CD3抗体，克隆UCHT1
    抗人CD3抗体，克隆UCHT1

    小鼠（BALB/c）单克隆IgG1抗体，抗人、黑猩猩CD3

质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.